Neurometabolic drug pipelines

Dainippon Sumitomo Pharma

Vatiquinone

Leigh syndrome

Phase III


Eisai

Lorcaserin

Obesity

Serotonin 2c receptor agonist

Approved


Takeda

TAK-831

cerebellar ataxia, schizophrenia

D- amino acid oxidase (DAAO) inhibitor

Phase I


Acorda Therapeutics

CVT-301

Parkinson’s disease

Phase III